

CLEARBRIDGE HEALTH LIMITED
(Company Registration No. 201001436C)

REGISTRATION OF FINAL OFFER DOCUMENT OF ASSOCIATED COMPANY, BIOLIDICS LIMITED (FORMERLY KNOWN AS CLEARBRIDGE BIOMEDICS PTE. LTD.)

The board of directors (the "**Board**") of Clearbridge Health Limited (the "**Company**") refers to the Company's announcements ("**Announcements**") dated 28 June 2018, 19 July 2018 and 26 November 2018 in relation to the Listing.

Further to the Announcements, the Board is pleased to announce that Biolidics had, on 11 December 2018, registered its final offer document with the Singapore Exchange Securities Trading Limited ("**SGX-ST**") acting as agent on behalf of the Monetary Authority of Singapore.

In conjunction with the Listing on the Catalist Board ("**Catalist**") of the SGX-ST, Biolidics will be offering 27,500,000 new shares via placement (the "**Placement Shares**") priced at S\$0.28 each (the "**Issue Price**") (the "**IPO**"). The Placement Shares represent approximately 11.34% of Biolidics' enlarged share capital of 242,500,000 shares. Upon completion of the IPO, Biolidics' market capitalisation is expected to be S\$67.9 million based on the Issue Price of S\$0.28 per Placement Share.

Please refer to the final offer document for full details on Biolidics and the Placement. A copy of the final offer document is available on the SGX-ST's websites at <http://www.sgx.com>.

Shareholders and other investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisors if there are in doubt about the actions they should take.

The Company will make further announcements as and when there are material updates and developments to the Listing.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Chief Executive Officer and Executive Director

11 December 2018

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The Sponsor has not independently verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*